Survivin Expression in Human Lung Cancer and the Influence of Its Downregulation on the Biological Behavior of Human Lung Cancer Cells

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2012 Sep 13

PMID 22970008

Citations 8

Authors

Xiang-Qi Chen

Sheng Yang

Ming-Qiang Kang

Zhi-Ying Li

Hui-Shan Lu

Ting-Yan Lin

Affiliations

Soon will be listed here.

Abstract

The aim of the present study was to detect the expression of survivin in human lung cancer and to investigate the influence of its downregulation on the biological behavior of A549 lung cancer cells. The high expression of survivin in human lung cancer was verified by immunohistochemistry. Survivin small interfering RNA (siRNA) and unrelated sequence were synthesized and the siRNA lentiviral vector was constructed. The vector was transfected into A549 lung cancer cells, in which the clone with stable expression was screened out. We blocked the expression of survivin mRNA and protein by RNA interference (RNAi) technique. The downregulation of survivin mRNA and protein expression was confirmed by real-time quantitative PCR and western blotting. The proliferative activity and growth rate of A549 cells were determined by colony formation assay and mononuclear cell direct cytotoxicity assay (MTT assay). The reconstituted basement membrane (RBM) penetrating capacity was determined by cell invasion assay. The cell movement and migratory capacity were detected by wound-healing repair assay. The results showed that the sequence-specific siRNA significantly downregulated the expression of survivin at both the mRNA and protein levels. Downregulation of survivin expression dramatically decreased the invasive and metastatic capacities of the cells, suppressed the proliferation, decelerated the rate of growth, reduced the number of clones on soft agar and decreased the capacity of RBM penetration and migration. In conclusion, survivin, which plays an important role in carcinogenesis and development of lung cancer, can be effectively downregulated using the RNAi technique.

Citing Articles

Identifying General Tumor and Specific Lung Cancer Biomarkers by Transcriptomic Analysis.

Otalora-Otalora B, Osuna-Garzon D, Carvajal-Parra M, Canas A, Montecino M, Lopez-Kleine L Biology (Basel). 2022; 11(7).

PMID: 36101460 PMC: 9313083. DOI: 10.3390/biology11071082.

Dinaciclib, a Bimodal Agent Effective against Endometrial Cancer.

Howard D, James D, Murphy K, Garcia-Parra J, Pan-Castillo B, Rex S Cancers (Basel). 2021; 13(5).

PMID: 33800911 PMC: 7962054. DOI: 10.3390/cancers13051135.

Discovery of Survivin Inhibitors Part 1: Screening the Harbor Branch Pure Compound Library.

Guzman E, Pitts T, Tandberg K, Winder P, Wright A Mar Drugs. 2021; 19(2).

PMID: 33573152 PMC: 7911841. DOI: 10.3390/md19020073.

Myricanol 5-fluorobenzyloxy ether regulation of survivin pathway inhibits human lung adenocarcinoma A549 cells growth in vitro.

Dai G, Chen X, Ren Z, Dai C, Tong Y, Chai K BMC Complement Med Ther. 2020; 20(1):269.

PMID: 32883260 PMC: 7470448. DOI: 10.1186/s12906-020-03062-8.

Anticancer Activity of Tetrandrine by Inducing Apoptosis in Human Breast Cancer Cell Line MDA-MB-231 In Vivo.

Wang C, Yang J, Guo Y, Shen J, Pei X Evid Based Complement Alternat Med. 2020; 2020:6823520.

PMID: 32714412 PMC: 7345956. DOI: 10.1155/2020/6823520.

References

Ashihara E . [RNA interference for cancer therapies]. Gan To Kagaku Ryoho. 2010; 37(11):2033-41. View

Hofmann H, Simm A, Hammer A, Silber R, Bartling B . Expression of inhibitors of apoptosis (IAP) proteins in non-small cell human lung cancer. J Cancer Res Clin Oncol. 2002; 128(10):554-60. DOI: 10.1007/s00432-002-0364-z. View

Srinivasula S, Ashwell J . IAPs: what's in a name?. Mol Cell. 2008; 30(2):123-35. PMC: 2677451. DOI: 10.1016/j.molcel.2008.03.008. View

Li C, Wu Z, Liu M, Pazgier M, Lu W . Chemically synthesized human survivin does not inhibit caspase-3. Protein Sci. 2008; 17(9):1624-9. PMC: 2525533. DOI: 10.1110/ps.036145.108. View

Dohi T, Xia F, Altieri D . Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. Mol Cell. 2007; 27(1):17-28. PMC: 1986705. DOI: 10.1016/j.molcel.2007.06.004. View

Nabilsi N, Broaddus R, Loose D . DNA methylation inhibits p53-mediated survivin repression. Oncogene. 2009; 28(19):2046-50. DOI: 10.1038/onc.2009.62. View

Altieri D . Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2007; 8(1):61-70. DOI: 10.1038/nrc2293. View

Akyurek N, Memis L, Ekinci O, Kokturk N, Ozturk C . Survivin expression in pre-invasive lesions and non-small cell lung carcinoma. Virchows Arch. 2006; 449(2):164-70. DOI: 10.1007/s00428-006-0239-9. View

Kanwar J, Kamalapuram S, Kanwar R . Targeting survivin in cancer: patent review. Expert Opin Ther Pat. 2010; 20(12):1723-37. DOI: 10.1517/13543776.2010.533657. View

10.

Mehrotra S, Languino L, Raskett C, Mercurio A, Dohi T, Altieri D . IAP regulation of metastasis. Cancer Cell. 2010; 17(1):53-64. PMC: 2818597. DOI: 10.1016/j.ccr.2009.11.021. View

11.

Small S, Keerthivasan G, Huang Z, Gurbuxani S, Crispino J . Overexpression of survivin initiates hematologic malignancies in vivo. Leukemia. 2010; 24(11):1920-6. PMC: 2978276. DOI: 10.1038/leu.2010.198. View

12.

Horn M, Waterhouse P . Rapid match-searching for gene silencing assessment. Bioinformatics. 2010; 26(16):1932-7. DOI: 10.1093/bioinformatics/btq318. View

13.

Varfolomeev E, Blankenship J, Wayson S, Fedorova A, Kayagaki N, Garg P . IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. 2007; 131(4):669-81. DOI: 10.1016/j.cell.2007.10.030. View

14.

Lee M, Kim D, Min N, Kim H . Akt1 inhibition by RNA interference sensitizes human non-small cell lung cancer cells to cisplatin. Int J Cancer. 2008; 122(10):2380-4. DOI: 10.1002/ijc.23371. View

15.

Alberg A, Nonemaker J . Who is at high risk for lung cancer? Population-level and individual-level perspectives. Semin Respir Crit Care Med. 2008; 29(3):223-32. PMC: 3399915. DOI: 10.1055/s-2008-1076742. View

16.

Altieri D . New wirings in the survivin networks. Oncogene. 2008; 27(48):6276-84. PMC: 2683067. DOI: 10.1038/onc.2008.303. View

17.

Jang J, Kim K, Kang K, Choi J, Lee W, Kim C . Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer. 2007; 60(1):31-39. DOI: 10.1016/j.lungcan.2007.09.008. View

18.

Zheng W, Ma X, Wei D, Wang T, Ma Y, Yang S . Molecular cloning and bioinformatics analysis of a novel spliced variant of survivin from human breast cancer cells. DNA Seq. 2005; 16(5):321-8. DOI: 10.1080/10425170500226490. View

19.

Sioud M . Promises and challenges in developing RNAi as a research tool and therapy. Methods Mol Biol. 2010; 703:173-87. DOI: 10.1007/978-1-59745-248-9_12. View